A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG)
A phase 3 trial of Gemcitabine intravesical system (TAR-200), Mitomycin C and Gemcitabine in bladder & urothelial cancer, run by Janssen Research & Development, LLC, active and no longer recruiting.
Overview
A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG) is a phase 3 interventional study registered as NCT06211764 by Janssen Research & Development, LLC, with 272 participants enrolled, started 2024-04-09 and due to reach its primary completion in 2030-11-27. Interventions recorded: TAR-200, Mitomycin C and Gemcitabine.
Similar pages
not linked directly; found by shared links- TrialEfficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)
Shares Mitomycin C, Gemcitabine, Bladder & urothelial cancer and the tag pipeline.
- TrialA Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer
Shares Johnson & Johnson, Gemcitabine, Bladder & urothelial cancer and the tag pipeline.
- TrialEnfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)
Shares Mitomycin C, Gemcitabine, Bladder & urothelial cancer and the tag pipeline.
- TrialA Study to Evaluate the Safety and Efficacy of NDV-01 in Participants With NMIBC
Shares Gemcitabine, Bladder & urothelial cancer and the tag pipeline.
- TrialAn Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial Cancer
Shares Johnson & Johnson, Bladder & urothelial cancer and the tag pipeline.
- TrialStudy of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer
Shares Johnson & Johnson, Bladder & urothelial cancer and the tag pipeline.
- TrialPhase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy
Shares Gemcitabine, Bladder & urothelial cancer and the tag pipeline.
- Trial9MW2821 in Combination With Toripalimab vs Standard Chemotherapy in Locally Advanced or Metastatic Urothelial Cancer
Shares Gemcitabine, Bladder & urothelial cancer and the tag pipeline.